Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, Pereslete A, Abravanel DL, Ferreira AR, Wrabel E, Helvie K, Hughes ME, Partridge AH, Overmoyer B, Lin NU, Tayob N, Tolaney SM, Wagle N. Gómez Tejeda Zañudo J, et al. Among authors: barroso sousa r. Nat Commun. 2024 Mar 19;15(1):2446. doi: 10.1038/s41467-024-45835-6. Nat Commun. 2024. PMID: 38503755 Free PMC article. Clinical Trial.
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, Johnson BE, Meyerson M, Jeselsohn R, Qiu X, Li R, Long H, Winer EP, Dillon D, Curigliano G, Cherniack AD, Tolaney SM, Lin NU. Tarantino P, et al. Among authors: barroso sousa r. Nat Commun. 2023 Dec 14;14(1):8321. doi: 10.1038/s41467-023-44124-y. Nat Commun. 2023. PMID: 38097580 Free PMC article. No abstract available.
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, Johnson BE, Meyerson M, Jeselsohn R, Qiu X, Li R, Long H, Winer EP, Dillon D, Curigliano G, Cherniack AD, Tolaney SM, Lin NU. Tarantino P, et al. Among authors: barroso sousa r. Nat Commun. 2023 Nov 18;14(1):7496. doi: 10.1038/s41467-023-43324-w. Nat Commun. 2023. PMID: 37980405 Free PMC article.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP. Tolaney SM, et al. Among authors: barroso sousa r. Lancet Oncol. 2023 Mar;24(3):273-285. doi: 10.1016/S1470-2045(23)00051-7. Lancet Oncol. 2023. PMID: 36858723 Clinical Trial.
Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil.
Queiroz MM, Sacardo KP, Ribeiro MF, Gadotti LL, Saddi R, Oliveira LJC, Linck RDM, Cruz MRS, Barroso-Sousa R, Sahade M, Correa TS, Mano MS, Suzuki DA, Shimada AK, Katz A. Queiroz MM, et al. Among authors: barroso sousa r. Cancer Treat Res Commun. 2023;35:100683. doi: 10.1016/j.ctarc.2023.100683. Epub 2023 Jan 19. Cancer Treat Res Commun. 2023. PMID: 36716534 Free article.
Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.
Oliveira LJC, Megid TBC, Rosa DD, Magliano CADS, Assad DX, Argolo DF, Sanches SM, Testa L, Bines J, Kaliks R, Caleffi M, de Melo Gagliato D, Sahade M, Barroso-Sousa R, Corrêa TS, Shimada AK, Batista DN, Musse Gomes D, Cesca MG, Gaudêncio D, Moura LMA, de Araújo JAP, Katz A, Mano MS. Oliveira LJC, et al. Among authors: barroso sousa r. Ther Adv Med Oncol. 2022 Dec 26;14:17588359221141760. doi: 10.1177/17588359221141760. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36601632 Free PMC article.
What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?
Leite ACR, Suzuki DA, Pereira AAL, Machado NP, Barroso-Sousa R, Correa TS, Moura FC, Morbeck IAP, Gumz BP, Faria LDBB, Fernandes GDS, Sandoval RL. Leite ACR, et al. Among authors: barroso sousa r. Front Oncol. 2022 Sep 5;12:963910. doi: 10.3389/fonc.2022.963910. eCollection 2022. Front Oncol. 2022. PMID: 36132150 Free PMC article.
PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling.
Wanderley CWS, Maganin AGM, Adjafre B, Mendes AS, Silva CEA, Quadros AU, Luiz JPM, Silva CMS, Silva NR, Oliveira FFB, Gomes FIF, Restrepo JLJ, Speck-Hernandez CA, Turaça F, Silva GVL, Pigatto GR, Nakaya HI, Mota JM, Barroso-Sousa R, Alves-Filho JC, Cunha TM, Cunha FQ. Wanderley CWS, et al. Among authors: barroso sousa r. Cancer Immunol Res. 2022 Nov 2;10(11):1299-1308. doi: 10.1158/2326-6066.CIR-22-0003. Cancer Immunol Res. 2022. PMID: 36083496
69 results